27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Moderna Inc (NASDAQ:MRNA) said that the FDA would require additional time to complete its assessment of its COVID-19 vaccine for use in adolescents aged 12 to 17 years.
- The FDA may not complete the Moderna's shot review before January 2022, dealing with a potential setback to the timing of an emergency use authorization (EUA) for that age group.
- The Company said that the FDA needed additional time to evaluate recent international analyses of the risk of myocarditis after vaccination.
- Related Link: FDA Revises Pfizer, Moderna COVID-19 Vaccine Sheets With Rare Heart Inflammation Warning.
- Moderna said it is reviewing new external analyses on the increased myocarditis risk in those under 18 years of age as they become available.
- Moderna also said it would delay filing its request for a EUA of 50 µg dose of the vaccine for children ages 6 to 11 years while the FDA completes its review of the 12-17 filing.
- Related: FDA May Clear First COVID-19 Vaccine For Younger Kids, Probably Today: NYT.
- Price Action: MRNA shares are down 3.20% at $334.15 during the premarket session on Monday's last check.
- Image by Spencer Davis from Pixabay
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!